Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 19;37(1):158.
doi: 10.1007/s40520-025-03049-w.

Gliflozines as add-on to Arni in echocardiographic, sarcopenic and oxidative stress parameters in elderly patients with chronic heart failure

Giuseppe Armentaro #  1 , Velia Cassano #  2 , Marcello Magurno  2 , Carlo Alberto Pastura  2 , Marcello Divino  3 , Giandomenico Severini  1 , Domenico Martire  2 , Sofia Miceli  1 , Raffaele Maio  1 , Elisa Mazza  2 , Tiziana Montalcini  4   5 , Arturo Pujia  2   5 , Angela Sciacqua  6   7   8
Affiliations

Gliflozines as add-on to Arni in echocardiographic, sarcopenic and oxidative stress parameters in elderly patients with chronic heart failure

Giuseppe Armentaro et al. Aging Clin Exp Res. .

Abstract

Background: Sarcopenia is common in patients with heart failure (HF) and it is frequently associated with other comorbidities. Sarcopenia has been linked to an increased risk of major adverse cardiovascular events (MACE) in HF patients.

Aims: The aim of the present study was to evaluate, in a cohort of older adult's patients affected by HF with reduced ejection fraction (HFrEF) and sarcopenia, already being treated with sacubitril/valsartan, the effect of add-on therapy with SGLT2i on clinical, functional abilities, muscle performance and effects on quality of life.

Methods: We enrolled 147 outpatients. A simple linear regression analysis was performed to assess the correlation between the change in Cardiac Index (CI) and Short physical performance battery (SPPB) values, expressed as (Δ) between baseline and follow-up (ΔT0-12), and several covariates.

Results: After 12 months of treatment, we observed an improvement in the inflammatory profile, moreover there was a reduction of the oxidative stress (p < 0.0001) and platelets activation (p < 0.0001) parameters. In addition, there was a significant increase in CI and global longitudinal strain and a statistically significant improvement in cognitive function, as shown by Mini-Mental State examination (MMSE) (p < 0.0001) score and SPPB (p < 0.0001). Considering ΔCI as dependent variation, Δ8-isoprotane resulted the major predictor, justifying 13.3% of its variation. When ΔSPPB was considered as dependent variable, Δ8-Isoprostane was the main predictor of ΔSPPB, justifying 54.6% of its variation.

Discussion and conclusions: This study demonstrated that the addition of SGLT2i to therapy leads to improvements in echocardiographic and sarcopenia-related parameters and biomarkers of oxidative stress and platelet activation.

Keywords: Cardiac index; Heart failure; SGLT2i; Sarcopenia.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: The protocol was approved by the University Ethics Committee (2022.384), and written informed consent was obtained from all participants to the “MAgna GraecIa evaluation of Comorbidities in patients with Heart Failure (MAGIC-HF)” study (ClinicalTrials.gov identifier: NCT05915364) and by the local Ethics Committee of Calabria Region, Italy (Catanzaro, Italy, document n. 263–23 July 2020). This study met the standards of good clinical practice (GCP) and the principles of the Declaration of Helsinki. Data sharing: The study is registered at ClinicalTrials.gov (NCT05915364). Researchers wishing to access data should contact the corresponding author. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Comparison between baseline and follow-up between biomarkers of oxidative stress and platelet activation. Data are mean ± SD. ****p < 0.0001 vs. baseline (A). Comparison between baseline and follow-up between markers of functional abilities and NT-proBNP. Data are mean ± SD. ****p < 0.0001 vs. baseline (B)
See this image and copyright information in PMC

References

    1. Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16–31 - PMC - PubMed
    1. Lena A, Anker MS, Springer J (2020) Muscle wasting and sarcopenia in heart failure—the current state of science. Int J Mol Sci 21:1–27 - PMC - PubMed
    1. Zhang Y, Zhang J, Ni W et al (2021) Sarcopenia in heart failure: a systematic review and meta-analysis. ESC Hear Fail 8:1007–1017 - PMC - PubMed
    1. Fonseca GWPD, dos Santos MR, de Souza FR et al (2020) Discriminating sarcopenia in overweight/obese male patients with heart failure: the influence of body mass index. ESC Hear Fail 7:84–91. 10.1002/ehf2.12545 - PMC - PubMed
    1. Bekfani T, Pellicori P, Morris DA et al (2016) Sarcopenia in patients with heart failure with preserved ejection fraction: impact on muscle strength, exercise capacity and quality of life. Int J Cardiol 222:41–46. 10.1016/j.ijcard.2016.07.135 - PubMed

MeSH terms

Substances

LinkOut - more resources